Recurrent Solid Neoplasm Recruiting Phase 1 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0080814 (Recurrent Solid Neoplasm)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03061188Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair GenesTreatment